Related Experiment Video

Updated: May 18, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Breast cancer molecular subtypes--modern therapeutic concepts for targeted therapy of a heterogeneous entity

Cornelia Liedtke1, Ludwig Kiesel

  • 1Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Münster, Münster, Germany. cornelia.liedtke@ukmuenster.de

Maturitas
|October 2, 2012
PubMed

Insights

Breast cancer is a complex disease with varied subtypes. This review summarizes emerging targeted therapies for hormone receptor-positive, HER2-positive, and triple-negative breast cancer, addressing treatment resistance and unmet needs.

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Therapeutics
  • Breast Cancer Research

Background:

  • Breast cancer is recognized as a heterogeneous disease with diverse molecular and clinical characteristics.
  • Current treatments benefit all patients unequally, leading to significant disease recurrence.
  • Specific challenges exist for hormone receptor-positive, HER2-positive (human epidermal growth factor receptor 2), and triple-negative breast cancer subtypes.

Purpose of the Study:

  • To review recent and ongoing development of targeted agents for breast cancer treatment.
  • To highlight therapeutic strategies addressing resistance in hormone receptor-positive and HER2-positive breast cancer.
  • To discuss the need for novel targeted options for triple-negative breast cancer.

Main Methods:

  • Literature review of recent advancements in targeted breast cancer therapies.
  • Analysis of molecular targets and clinical trial data for emerging agents.
  • Synthesis of information on therapeutic resistance mechanisms and novel drug development.

Main Results:

  • Identification of several promising targeted agents in various stages of development.
  • Understanding of strategies to overcome endocrine and anti-HER2/neu therapy resistance.
  • Recognition of the critical need for new targeted therapies for triple-negative breast cancer.

Conclusions:

  • Targeted therapies offer significant promise for improving breast cancer treatment outcomes.
  • Addressing therapeutic resistance and developing novel agents for all subtypes, especially triple-negative breast cancer, remains a priority.
  • Continued research into molecular heterogeneity is crucial for personalized breast cancer treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...